HPV-based screening provides greater protection against cervical cancer 21 (CC) than cytology-based strategies. Currently, several molecular diagnostic 22 assays for the detection of human papillomavirus (HPV) are available. In this 23 study, we analyzed 5 different HPV testing and genotyping techniques (Hybrid 24 Capture 2 [HC2; Qiagen, Hilden, Germany ], AnyplexTMII HPV28 [Anyplex; 25 Seegene, Seoul, Korea], Linear Array [Roche, Branchburg, NJ, USA], 26 GP5+/6+ PCR-EIA-RH [Labo Bio-medical Products, Rijswijk, The Netherlands] 27 and CLART2 [Genomica, Madrid, Spain]) in 295 women referred to the 28 hospital Colposcopy Clinic from 2007 to 2008 due to positive HPV test results 29 or an abnormal Pap test. DNA extraction for HPV genotyping was performed 30 in cervical sample specimens after Pap test and HPV detection by HC2. The 31 inclusion criteria were: (1) adequate cervical sampling with sufficient material 32 for the Pap test and HPV detection and genotyping, and (2) colposcopically-33 directed biopsy and/or endocervical curettage. HC2 showed the highest 34 sensitivity for high-grade squamous intraepithelial lesion and CC (HSIL+) 35 detection (96.1%), but all the HPV genotyping tests showed a higher 36 specificity. (Anyplex 86.8%; Linear Array 86.0%; GP5+/6+ 78.8%; CLART2 37 76.5%). The agreement between HC2 results and the other techniques was 38 similar: (82.4%, kappa = 0.650 for Anyplex; 83.4%, kappa = 0.670 for Linear 39 Array, 79.93%, kappa = 0.609 for GP5+/6+ and 82.4%, kappa=0.654 for 40 CLART2. HPV 16 and/or 18 infection was a risk factor for underlying HSIL+ in 41 the univariate analysis. Anyplex showed the highest risk of underlying HSIL+ 42 after positive HPV 16 and/or 18 tests (OR 31.1; 95% IC 12.1-80.0).
INTRODUCTION
After the initial processing that included the Pap test and HC2 testing the 139 residual material was centrifuged and the pellets stored at -80ºC until 140 processing. For all the other genotyping tests DNA extraction was performed 141 using 250µL of the cervical sample specimen to obtain 100 µL of eluate with 142 the QIAamp MinElute Virus Spin kit (QIAgen Inc., Valencia, CA, USA) 143 according to the manufacturer's protocol. DNA yields were quantified 144 spectrophotometrically using the Nanodrop ND-1000 (NanoDrop 145 Technologies, USA). A negative and a positive internal control were used in 146 each genotyping assay according to the manufacturer's procedure. All 147 genotyping assays were tested twice with each sample. A sample was 148 considered invalid for an specific test when both results were invalid. 149 Anyplex II HPV28 (Anyplex) was performed according to the 150 manufacturer's instructions with using 5 μl DNA in each of the two 20μl 151 reaction mixtures with primer set A or B and a CFX96 real-time thermocycler 152 (Bio-Rad, Hercules, CA, USA). A-set has 14 hr-HPV types (16, 18, 31, 33, 35, 153 39, 45, 51, 52, 56, 58, 59, 66, and 68 ) and B-set covers five HR and nine LR 154 types (26, 53, 69, 73, 82, 6, 11, 40, 42, 43, 44, 54, 61, and 70) . Anyplex uses 155 the Tagging Oligonucleotide Cleavage and Extension (TOCE) technology 156 (Seegene, Seoul, Korea) a novel approach that enables the detection of cycles of denaturation at 95ºC for 30 seconds, annealing at 60ºC for 1 minute, 163 and elongation at 72ºC for 30 seconds. 164 Linear Array HPV genotyping test (Linear Array) . This assay recognizes 165 the following HPV types: hr-HPV types 16, 18, 31, 33, 35, 39, 43, 44, 45, 51, 166 52, 56, 58, 59, 11, 26, 40, 42, 53, 54, 55, 61, 62, 167 64, 66, 67, 69, 70, 71, 72, 81, 73, 82, 83, 84, and IS39 and CP6108. (30) 168 Amplification, hybridization, and detection steps were performed as 169 recommended by the manufacturer. Briefly, ten μL of extracted DNA was 170 employed in the PCR reaction. PCR was performed in a final reaction volume 171 of 100 μl. The mixture was incubated for 2 minutes at 50°C and for 9 minutes 172 at 95°C, followed by 40 cycles of denaturation at 95ºC for 30 seconds, 173 annealing at 95°C for 30 seconds, and elongation at 72ºC for 1 minute. 174 GP5+/6+ PCR-EIA-RH (GP5+/6+). Ten μL of isolated DNA were amplified by 175 the GP5+/6+ PCR, and hr-HPV was detected by the EIA (Diassay, Rijswijk,
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The Netherlands) according to the manufacturer's instructions. (31) GP5+/6+ 177 PCR was performed in a total volumen of 50 μl. The mixture underwent 4 178 minutes denaturation step at 94°C, followed by 40 cycles of denaturation at 179 94°C for 20 seconds, annealing at 40 °C for 2 minutes and a chain elongation 180 step at 72°C for 1 minutes. The first cycle was preceded by a 4 min 181 denaturation at 94 °C and the last cycle was extended by a 4 min elongation at 182 72 °C. (32) Fourteen hr-HPV types can be targeted with the GP5+/6+ test: 183 HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 . After GP5+/6+ 184 PCR, EIA was performed. Three times the mean OD of the PCR negative 185 controls (OD ≤0.120) was used as the cut-off value to classify samples as 186 positive for HPV. This assay does not identify HPV genotypes individually.
Thus, next, the EIA-positive GP5+/6+ amplimers were genotyped by Reverse 188 Hybridization using Line Probe Assay, according to the manufacturer's 189 instructions. Briefly, ten μl of the biotinylated products of PCR were mixed in 190 test troughs and incubated at room temperature for 5 minutes after that, 1ml of 191 the prewarmed (37°C) hybridization solution and one strip was added to each 192 trough. Hybridization was performed for 1hour at 50ºC in a closed water bath 193 with back-and-forth shaking. The strips were washed twice with 1ml of wash 194 solution, at room temperature for 20 seconds and once at 50°C for 30 minutes.
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After the washing step, strips were rinsed twice with 1ml of a standard rinse (type 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 208 73, 82, 85) and 15 lr-HPVs (6, 11, 40, 42, 43, 44, 54, 61, 62, 71, 72, 81, 83, 209 84, 89). The test was performed according to the manufacturer's instructions. The present study compared different HPV tests in a routine diagnostic 294 setting. HC2 showed the highest sensitivity for HSIL+ detection while the 295 sensitivity of Anyplex and Linear Array was 90% of that shown by the HC2 296 test, (36) and they could therefore be considered candidate tests for CC 297 screening according to the international guidelines for HPV test validation. On 298 the other hand, CLART2 and GP5+/6+ showed a lower sensitivity, although 299 the latter showed the highest specificity. Patients under 30 years of age 300 present a high prevalence of HSIL lesions, (15) most of which regress and are 301 not the objective of CC screening strategies. Thus, the lower sensitivity of 302 CLART2 and GP5+/6+ could be helpful in this specific age group. All the HPV 303 tests showed a higher sensitivity than the cited 51% benchmark of cytology 304 sensitivity as a stand-alone test. (9;37) All HPV genotyping tests showed a 305 higher specificity than HC2 for the detection of HSIL+. The similar clinical 306 sensitivity and superior or equal specificity of the four HPV genotyping tests 307 compared to HC2, observed in primary screening, is in agreement with the 308 findings from previous studies on its performance in the triage of women with 309 minor cytological abnormalities. (12;29;36;38) 
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The agreement in terms of positivity/negativity of the different HPV 311 genotyping tests compared with HC2 was about 80% or higher. The high 312 agreement between the tests is in line with previous comparative reports. 43) Similarly, genotype concordance was over 80%. Different HPV types were 314 found in less than 5% of the HPV positive samples. Despite the different HPV 315 types included in each test and the differences in terms of sensitivity and 316 specificity, high concordance has been also reported between genotype 317 distribution in previous studies. (38;39;41-44) 318 In the present study, the rate of multiple HPV infections significantly 319 varied from 20.4% to 44.0% depending on the test used. This is in line with 320 previous studies comparing different methods for HPV typing and describing 321 considerable differences in the multiple infection rates of the individual tests.
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These series have shown that 15% to 50% of women with prevalent SIL of all Anyplex: Anyplex TMII HPV28; GP5+/6+: GP5+/6+ PCR-EIA-RH 
